The rise of Viagra initially drove a boom for pharma, however recent changes present a uncertain outlook for investors. Lower-cost versions are eroding earnings, and ongoing litigation add additional complexity to the https://flynnbwtn128143.bloggactif.com/42641182/the-blue-pill-and-pharma-a-precarious-bet